HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines

References

• O’Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12:201.
   PubMed Web of Science ®Google Scholar
• Giannakakis A, Coukos G, Hatzigeorgiou A, et al. miRNA genetic alterations in human cancers. Expert Opin Biol Ther. 2007;7:1375–1386.
   PubMed Web of Science ®Google Scholar
• Tang J, Ahmad A, Sarkar FH. The role of microRNAs in breast cancer migration, invasion and metastasis. IJMS. 2012;13:13414–13437.
   Web of Science ®Google Scholar
• Khoshnaw SM, Green AR, Powe DG, et al. MicroRNA involvement in the pathogenesis and management of breast cancer. J Clin Pathol. 2009;62:422–428.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–8707.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Casalini P, Piovan C, et al. Breast cancer and microRNAs: therapeutic impact. Breast. 2011;20(Suppl. 3):S63–S70.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao X, Wei F, et al. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene. 2014;533:389–397.
   PubMed Web of Science ®Google Scholar
• Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev. 2009;35:328–334.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–7070.
   PubMed Web of Science ®Google Scholar
• Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 2009;285:116–126.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704–714.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–1150.
   Google Scholar
• Eroles P, Bosch A, Perez-Fidalgo JA, et al. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38:698–707.
   PubMed Web of Science ®Google Scholar
• Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2016. DOI:10.1016/S0140-6736(16)32417-5
   Google Scholar
• Hannafon BN, Trigoso YD, Calloway CL, et al. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 2016;18:90.
   PubMed Web of Science ®Google Scholar
• Yang Y, Guo JX, Shao ZQ. miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study. Asian Pac J Trop Med. 2017;10:87–91.
   PubMed Web of Science ®Google Scholar
• Liang Y, Yang W, Zhu Y, et al. Prognostic role of microRNA-203 in various carcinomas: evidence from a meta-analysis involving 13 studies. Springerplus. 2016;5:1538.
   PubMed Web of Science ®Google Scholar
• Tommasi S, Mangia A, Lacalamita R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer. 2007;120:2078–2085.
   PubMed Web of Science ®Google Scholar
• Zuo KQ, Zhang XP, Zou J, et al. Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res. 2010;38:1428–1435.
   PubMed Web of Science ®Google Scholar
• Shah MY, Pan X, Fix LN, et al. 5-Fluorouracil drug alters the microRNA expression profiles in MCF-7 breast cancer cells. J Cell Physiol. 2011;226:1868–1878.
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Sato F, Terasawa K, et al. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PloS One. 2012;7:e31422.
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14:2348–2360.
   PubMed Web of Science ®Google Scholar
• Kuang Y, Nie YJ. Exploration of the regulatory effect of miR-21 on breast cancer cell line proliferation and invasion as well as the downstream target genes. Asian Pac J Trop Med. 2016;9:470–473.
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–436.
   PubMed Web of Science ®Google Scholar
• Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010;126:73–80.
   PubMed Web of Science ®Google Scholar
• Gottardo F, Liu CG, Ferracin M, e al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007:25:387–92.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang B, Li W, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer. 2011;2:782–791.
   PubMedGoogle Scholar
• Ru P, Steele R, Hsueh EC, et al. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer. 2011;2:720–727.
   PubMedGoogle Scholar
• Bueno MJ, de Castro IP, de Cedrón MG, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496–506.
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng X, Shen C, et al. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712.
   PubMed Web of Science ®Google Scholar
• Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599–605.
   PubMed Web of Science ®Google Scholar
• Gusterson B, Gelber R, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. JCO. 1992;10:1049–1056.
   PubMed Web of Science ®Google Scholar
• Jarvinen T, Holli K, Kuukasjarvi T, et al. Predictive value of topoisomerase IIa and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer. 1998;77:2267–2273.
   PubMed Web of Science ®Google Scholar
• Yu D, Liu B, Jing T, et al. Overexpression of both p185 c-erbB2 and p170 mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998;16:2087–2094.
   PubMed Web of Science ®Google Scholar
• Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996;13:1359–1365.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Pomatico G, et al. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer. 2000;85:710–715.
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825–2831.
   PubMed Web of Science ®Google Scholar
• Lee S, Yang W, Lan K-H, et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res. 2002;62:5703–5710.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lau Y-K, Xia W, et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res. 1999;5:343–353.
   PubMed Web of Science ®Google Scholar
• Ueno NT, Yu D, Hung M-C. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 1997;15:953–960.
   PubMed Web of Science ®Google Scholar
• Zhou M, Liu Z, Zhao Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010;285:21496–21507.
   PubMed Web of Science ®Google Scholar